News

How Medtech Companies are Unlocking the Potential of Latin America in Clinical Research
Julio G. Martinez-Clark Julio G. Martinez-Clark

How Medtech Companies are Unlocking the Potential of Latin America in Clinical Research

Medtech startups' challenges in the medical device industry in the US are multifaceted, ranging from regulatory hurdles to limited financial resources and prolonged subject recruitment timelines. US Medtech companies face professionalism, language barriers, fragmentation of resources, and lack of CRO corporate structures in Latin America. This impedes Latin American hospitals from having seamless communication and collaboration with American clinical trial clients, particularly in the medical device first-in-human clinical trial industry. These factors underscore the urgent need for a solution-driven approach to bridge the gap between innovation and execution in Latin America.

Read More
Imperative Care Obtains Colombia Approval for its ADVANCE First-In-Human study
Julio G. Martinez-Clark Julio G. Martinez-Clark

Imperative Care Obtains Colombia Approval for its ADVANCE First-In-Human study

On September 28, 2023, INVIMA, the regulatory agency of Colombia, approved Imperative Care, Inc.'s ADVANCE first-in-human study, which will be conducted at one research center in Cartagena. The ADVANCE study aims to recruit up to 15 subjects from Colombia and will last for approximately five years.

Read More
Greenlight Guru and bioaccess® Partner to Accelerate Market Access and Improve Patient Outcomes in Latin America and Beyond
Julio G. Martinez-Clark Julio G. Martinez-Clark

Greenlight Guru and bioaccess® Partner to Accelerate Market Access and Improve Patient Outcomes in Latin America and Beyond

Greenlight Guru and bioaccess® share the same goal and mission: to enhance the quality of life by helping Medtech manufacturers get to market faster and with less risk. Greenlight Guru and bioaccess® announce their cooperation agreement to bring medical device companies closer to Latin America, conduct early-stage clinical trials, or sell their innovations.

Read More